Zobrazeno 1 - 10
of 80
pro vyhledávání: '"O Kong"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M. Lodari, O. Kong, M. Rendell, A. Tosato, A. Sammak, M. Veldhorst, A. R. Hamilton, G. Scappucci
Publikováno v:
Applied Physics Letters, 120(12)
We demonstrate that a lightly strained germanium channel ([Formula: see text]) in an undoped Ge/Si0.1Ge0.9 heterostructure field effect transistor supports a two-dimensional (2D) hole gas with mobility in excess of [Formula: see text] cm2/Vs and perc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bebda8a532f797f070d97112ffe3d11
http://arxiv.org/abs/2112.11860
http://arxiv.org/abs/2112.11860
Autor:
Debu Tripathy, S-A Im, Aditya Bardia, Francisco J. Esteva, M. Campone, S Chia, W Bao, O Kong, Andrew T. Chan, D. A. Yardley, I Diaz-Padilla, H. A. Burris, K Rodriguez Lorenc
Publikováno v:
Cancer Research. 79:P6-18
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone
Autor:
O Kong, Aditya Bardia, Brad Lanoue, Francisco J. Esteva, JT Beck, Nadia Harbeck, Joyce A. O'Shaughnessy, J. Alam, S Hurvitz, S Chia, David Chandiwana, S. Verma, Patrick Neven
Publikováno v:
Cancer Research. 79:P6-18
Background: In the Phase III MONALEESA (ML) trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + endocrine therapy (ET) significantly improved progression-free survival (PFS) vs placebo (PBO) + ET in patients (pts) with hormone receptor-
Autor:
J. Alam, Patrick Neven, Joohyuk Sohn, Thomas Bachelot, I Diaz-Padilla, M. Martin, Saúl Campos-Gómez, O Kong, Gabe S. Sonke, Aditya Bardia, Andrew T. Chan, M. Miller, Lowell L. Hart, JT Beck
Publikováno v:
Cancer Research. 79:P6-18
Background: In the MONALEESA (ML) trials, addition of ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) prolonged progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (H
Autor:
Debu Tripathy, S Hurvitz, Fabio Franke, Y-S Lu, Fatima Cardoso, I Diaz-Padilla, FM Cruz, A. Gaur, Saúl Campos-Gómez, Aditya Bardia, Paul Wheatley-Price, O Kong, M. Miller, Roberto Hegg
Publikováno v:
Cancer Research. 79:P6-18
Background: Younger patients (pts) with breast cancer may experience more aggressive disease and are more likely to die from their cancer vs older pts. In the Phase III MONALEESA-7 study (NCT02278120), the addition of ribociclib (RIB; cyclin-dependen
Autor:
W Bao, S Chia, DJ Slamon, Gabriel N. Hortobagyi, S-A Im, O Kong, Francisco J. Esteva, S Hurvitz, Debu Tripathy, D. A. Yardley, Andrew T. Chan, I Diaz-Padilla, K Rodriguez Lorenc
Publikováno v:
Cancer Research. 79:P6-18
Background: In three separate Phase III randomized, placebo-controlled trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners prolonged progression-free survival (PFS) vs placebo (PBO) + ET in patien
Autor:
Francisco J. Esteva, Andrew T. Chan, O Kong, Paul Wheatley-Price, Arnd Nusch, Y-S Yap, DJ Slamon, H. A. Burris, K Rodriguez Lorenc, D. A. Yardley, A Gaur, I Diaz-Padilla, Thomas Bachelot, Gabe S. Sonke
Publikováno v:
Cancer Research. 79:P6-18
Background: Patients (pts) with advanced breast cancer (ABC) who present with visceral metastases (mets) have a poorer prognosis vs pts with non-visceral disease. In the Phase III MONALEESA (ML) trials, ribociclib (RIB) + endocrine therapy (ET) prolo
Autor:
Antonia Ridolfi, C Nienstedt, N. Turner, O Kong, Dejan Juric, Stephen Chia, Eva Ciruelos, B Sankaran, HS Rugo
Publikováno v:
Cancer Research. 78:OT3-05
Background: Endocrine therapy (ET) is the standard of care for treatment of HR+, HER2– aBC. However, ET resistance occurs frequently leading to disease progression. Dysregulation of the PI3K/AKT/mTOR pathway, specifically mutations in PIK3CA, the g